GB672510A - Improvements in or relating to the purification of aureomycin - Google Patents
Improvements in or relating to the purification of aureomycinInfo
- Publication number
- GB672510A GB672510A GB18130/50A GB1813050A GB672510A GB 672510 A GB672510 A GB 672510A GB 18130/50 A GB18130/50 A GB 18130/50A GB 1813050 A GB1813050 A GB 1813050A GB 672510 A GB672510 A GB 672510A
- Authority
- GB
- United Kingdom
- Prior art keywords
- aureomycin
- mash
- alcohol
- extract
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Aureomycin in the form of an acid salt is isolated from an aqueous aureomycin solution, having a pH of less than 4 and containing at least 0.3 mg. of aureomycin per ml., by adding to such a solution a water-soluble inorganic salt and a mono- or poly-hydric alcohol or an ester or ether thereof as solvent for the aureomycin the amount of salt being preferably substantially sufficient to saturate said aqueous solution and the amount of organic solvent being preferably insufficient to appreciably dissolve or extract the aureomycin, and separating the resulting acid salt of aureomycin. It is preferred that the aureomycin concentration be 0.3 to 30 mg. per ml., the pH between 1 and 4 and the organic solvent butanol in the proportions of not more than 10 per cent, and preferably 5 per cent, by volume. The aureomycin solution may be prepared from the fermentation mash of Streptomyces aureofaciens or other aureomycin producing organism by: (a) acidifying the mash with mineral acid to a pH below 4, adding a filtration aid, e.g. fuller's earth, filtering and evaporating the filtrate in vacuo below 50 DEG C. and preferably between 20 DEG and 40 DEG C.; (b) treating the mash with calcium, strontium, barium or magnesium ions at a pH 6 to 11, and preferably 7 to 9, adding fuller's earth and filtering, the cake so formed being extracted with mineral acid and the extract concentrated as in (a); and (c) extracting the mash with a water-miscible organic solvent containing mineral acid, e.g. ketones, such as acetone and aliphatic alcohols such as ethanol, removing the solvent from the extract and concentrating the extract as in (a). The organic solvents for the aureomycin which are used in the formation of the acid salts may be anhydrous ethanol, methanol, isopropanol, b -ethoxyethanol, n-butanol, sec.-butanol, amyl alcohol, hexyl alcohol, capryl alcohol, octyl alcohol and decanol, of which the substantially water-insoluble solvents are preferred. The inorganic salts may be sodium chloride, ammonium chloride, lithium chloride, potassium chloride, calcium chloride, sodium sulphate, ammonium sulphate, lithium sulphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, of which the chlorides are preferred.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US672510XA | 1949-08-20 | 1949-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB672510A true GB672510A (en) | 1952-05-21 |
Family
ID=22074745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB18130/50A Expired GB672510A (en) | 1949-08-20 | 1950-07-20 | Improvements in or relating to the purification of aureomycin |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB672510A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3017323A (en) * | 1957-07-02 | 1962-01-16 | Pfizer & Co C | Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics |
CN101863797A (en) * | 2010-07-07 | 2010-10-20 | 福建省福抗药业股份有限公司 | New process for preparing chlortetracycline hydrochloride |
CN114848599A (en) * | 2022-06-09 | 2022-08-05 | 驻马店华中正大有限公司 | High-stability aureomycin premix and preparation method thereof |
-
1950
- 1950-07-20 GB GB18130/50A patent/GB672510A/en not_active Expired
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3017323A (en) * | 1957-07-02 | 1962-01-16 | Pfizer & Co C | Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics |
CN101863797A (en) * | 2010-07-07 | 2010-10-20 | 福建省福抗药业股份有限公司 | New process for preparing chlortetracycline hydrochloride |
CN101863797B (en) * | 2010-07-07 | 2013-04-24 | 福建省福抗药业股份有限公司 | New process for preparing chlortetracycline hydrochloride |
CN114848599A (en) * | 2022-06-09 | 2022-08-05 | 驻马店华中正大有限公司 | High-stability aureomycin premix and preparation method thereof |
CN114848599B (en) * | 2022-06-09 | 2023-10-13 | 驻马店华中正大有限公司 | High-stability aureomycin premix and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB672510A (en) | Improvements in or relating to the purification of aureomycin | |
Underkofler et al. | The production of dihydroxyacetone by the action of Acetobacter suboxydans upon glycerol | |
GB683423A (en) | Improvements in and relating to antibiotic substances produced by group n streptococcus lactis | |
GB1404546A (en) | Process for purifying commercial-grade phosphoric acid by extraction | |
GB1357614A (en) | Purification of phosphoric acid | |
GB977327A (en) | An antibiotic moenomycin and a process for its manufacture | |
US3907869A (en) | Method of producing calcium pangamate | |
GB746534A (en) | A process for the separation of monoalkyl phosphates from dialkyl phosphates | |
GB1412691A (en) | Recovery of bacitracin | |
GB1472970A (en) | Purfified phosphoric acid and its production | |
GB552619A (en) | Improvements relating to bactericidal substances | |
GB1275345A (en) | PROCESS FOR THE MANUFACTURE OF MONO-ALKALI AND DI-ALKALI METAL SALTS OF alpha-CARBOXYBENZYLPENICILLIN | |
GB578590A (en) | Improvements in or relating to the preparation of penicillin salts | |
DE420910C (en) | Process for the preparation of double compounds from aliphatic amino acids and inorganic alkali salts | |
GB1237710A (en) | Process for manufacturing sodium tripolyphosphate | |
GB772149A (en) | Production of a new antibiotic bromotetracycline by fermentation | |
GB1365362A (en) | Process for producing cirtic acid | |
GB555450A (en) | Process for the preparation of active glucosides of senna | |
US2443962A (en) | Method of producing antibiotic substance | |
GB1018342A (en) | Production of purified preparations of the kallikrein inactivator | |
GB770248A (en) | Improvements in or relating to the preparation of bacitracin | |
GB822667A (en) | Process for the preparation of common salt by the evaporation of solutions | |
GB463698A (en) | Process for the manufacture of a vitamin preparation | |
GB678508A (en) | Preparation of crystalline benzylpenicillinic acid-diisopropyl etherate | |
GB496248A (en) | Pancreas-derived product and process of producing it |